SIRT3 and metabolic dysfunction-associated steatotic liver disease: Although there is yet little evidence about whether the mechanism described in this study operates in human NAFLD, it has been reported that a unique single nucleotide polymorphism in the SIRT3 gene results in reduced SIRT3 enzymatic efficiency and an increased risk of developing metabolic syndrome and hepatic steatosis in humans [6].